Abstract:Based on our hypothesis that epitope vaccine may be a new strategy to induce high levels of neutralization antibodies against HIV–1, we prepared multiple–epitope vaccines using three neutralizing epitopes (GPGRAFY, RILAVERYLKD and ELDKWA) of HIV–1 gp160, and characterized their immunogenicity. Peptide 1 [C–G–(ELDKWA–GPGRAFY)2–K] and peptide 2 (CG–GPGRAFY–ELDKWA–G–RILAVERYLKD) were synthesized and conjugated with carrier protein bovine serum albumin (BSA). After vaccination antibody responses to these immunogens were induced and evaluated by ELISA. The C–G–(ELDKWA–GPGRAFY)2–K–BSA (BSA: carrier protein) multiple–epitope vaccine induced a strong antibody response to the C–G–(ELDKWA–GPGRAFY)2–K peptide (antibody titer: 1:25,600) and C–(ELDKWAG)4 peptide (antibody titer: 1:12,800), but a weak antibody response to the C–(GPCGRAFY)4 peptide. The CG–GPGRAFY–ELDKWA–G–RILAVERYLKD–K–BSA (BSA: carrier protein) multiple–epitope vaccine also induced strong antibody response to the CG–GPGRAFY–ELDKWA–G–RILAVERYLKD–K peptide (antibody titer: 1:25,600) and C–(ELLDKWAG)4 peptide (antibody titer: 1:6,400), a very strong response to C–(RIVALVERYLKD–G)2–K peptide (dilution: 1:102,400), and a very weak response to the C–(GPGRAFY)4 peptide (dilution: 1:400) in mice. Both antisera induced by both multiple–epitope vaccines interacted with the recombinant soluble gp41 (rgp41), but did not bind two control peptides. In comparison with both epitope vaccines, the rgp160 subunit vaccine could induce weak epitope–specific antibody response to these three epitopes on the three epitope peptides and V3, N–domain and C–domain peptides (dilution: 1:400–1:1,600). These results indicate that both multiple–epitope vaccines could induce high levels of antibodies to both neutralizing epitopes RILAVERYLKD and ELDKWA, while the GPGRAFY epitope on both vaccines appeared to have weak immunogenicity. Both multiple–epitope vaccines showed significant potency on inducing high levels of epitope–specific neutralization antibodies in comparison with rgp160 subunit vaccine.

Induction of High Levels of Antibodies Recognizing the Neutralizing Epitope Eldkwa and the D- or K-Position-Mutated Epitopes by Candidate Epitope Vaccines Against Hiv-1

ELNKWA-epitope Specific Antibodies Induced by Epitope-Vaccine Recognize ELDKWA- and Other Two Neutralizing-Resistant Mutated Epitopes on HIV-1 Gp41

Epitope-Vaccine Induces High Levels of Eldkwa-Epitope-Specific Neutralizing Antibody

Induction of High Level of Specific Antibody Response to the Neutralizing Epitope ELDKWA on HIV-1 Gp41 by Peptide-Vaccine☆

Immunogenicity of Neutralizing Epitopes on Multiple–Epitope Vaccines Against HIV–1

Recombinant Multi-Epitope Vaccine Induce Predefined Epitope-Specific Antibodies Against HIV-1

The Recombinant Immunogen with High‐Density Epitopes of ELDKWA and ELDEWA Induced Antibodies Recognizing Both Epitopes on HIV‐1 Gp41

Epitope-Vaccines: A New Strategy to Induce High Levels of Neutralizing Antibodies Against Hiv-1

The Neutralizing Epitope ELDKWA on HIV-1 Gp41: Genetic Variability and Antigenicity

Repeated Epitope In The Recombinant Epitope-Peptide Could Enhance Eldkwa-Epitope-Specific Antibody Response

Characterization of Antibody Responses Against the 2F5 Epitope ELDKWA sing HIV-1 Env-Mediated Membrane Fusion and Neutralization Assays

Induction of Multi-Epitopespecific Antibodies Against HIV-1 by Multi-Epitopevaccines

Neutralizing Epitopes in the Membrane-Proximal Region of Hiv-1 Gp41: Genetic Variability and Co-Variation

Induction of High Levels of Epitope-Specific Antibodies by Epitope/peptide Candidate Vaccines Against Human Immunodeficiency Virus Type-1 (HIV-1).

Neutralization of HIV-1 Primary Isolate by ELDKWA-specific Murine Monoclonal Antibodies.

A predefined epitope-specific monoclonal antibody recognizes ELDEWA-epitope just presenting on gp41 of HIV-1 O clade.

HIV Epitope-Peptides in Aluminum Adjuvant Induced High Levels of Epitope-Specific Antibodies.

An Immunogen Containing Four Tandem 10E8 Epitope Repeats with Exposed Key Residues Induces Antibodies That Neutralize HIV-1 and Activates an ADCC Reporter Gene.

ELDKWA-epitope-specific monoclonal antibodies inhibit HIV env-mediated syncytium formation.

Mucosal Antibodies Induced by Tandem Repeat of 2f5 Epitope Block Transcytosis of Hiv-1

Targeting a Neutralizing Epitope of HIV Envelope Gp120 by Immune Complex Vaccine